azenosertib
zentalis pharma
['azenosertib', 'zentalisp']
today, zentalis will present preclinical data at the annual meeting 2023 that supports cyclin e1 as a predictive marker for treatment with azenosertib, the company s potentially first-in-class wee1 inhibitor product candidate. learn more: #aacr23 
Developing small molecule #therapeutics targeting fundamental biological pathways of #cancers